title: Matrine inhibits the migratory and invasive properties of nasopharyngeal carcinoma cells.
abstract: Matrine is a widely used Chinese herbal medicine that has historically been used in the treatment of inflammation and cancer. However, the antimetastatic effects and associated molecular mechanisms of matrine on nasopharyngeal carcinoma (NPC) remain to be elucidated. Therefore, the aims of the present study were to assess the antimetastatic effects of matrine on NPC, and identify the underlying mechanisms. Matrine inhibited the proliferation of NPC cells in vitro and in vivo. Furthermore, matrine inhibited the migration and invasion of NPC tumor cells at doses below the toxic range. Following treatment with matrine for 24 h, there was a decrease in the protein expression levels and activities of matrix metalloproteinase (MMP)‑2 and MMP‑9 in NPC‑039 cells. In addition, matrine markedly reduced the expression levels of p65 and p50 in the nuclei. Combined treatment of matrine with helenalin, a nuclear factor‑κB (NF‑κB) inhibitor resulted in a synergistic reduction in MMP‑2 and MMP‑9 expression levels, and the invasive capabilities of the NPC‑039 cells were also reduced. In conclusion, matrine inhibits NPC cell migration and invasion by suppressing the NF‑κB pathway. These results suggest that matrine may be a potential therapeutic agent for NPC.
authors: Department of Otolaryngology-Head and Neck Surgery, Second Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.
authors: Bin
authors: B
authors: Sun
authors: Department of Otolaryngology-Head and Neck Surgery, Second Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.
authors: Min
authors: M
authors: Xu
mesh_terms: D000470:Alkaloids / Q000627:therapeutic use*; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D002277:Carcinoma; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects*; D049109:Cell Proliferation / Q000187:drug effects; D006801:Humans; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D009305:Nasopharynx / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D009361:Neoplasm Invasiveness / Q000473:pathology / Q000517:prevention & control*; D011807:Quinolizines / Q000627:therapeutic use*; D000093842:Matrines
chemical_list: D000470:Alkaloids; D000972:Antineoplastic Agents, Phytogenic; D011807:Quinolizines; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9; D000093842:Matrines
references: Biochim Biophys Acta. 2005 May 25;1755(1):37-69
references: 15907591
references: Bioorg Med Chem Lett. 2010 Dec 15;20(24):7537-9
references: 21036613
references: Int J Oncol. 2013 Apr;42(4):1417-26
references: 23404079
references: Brain Res. 2012 May 15;1454:48-64
references: 22503072
references: Hepatobiliary Pancreat Dis Int. 2004 Feb;3(1):69-72
references: 14969841
references: Cancer. 2001 Dec 1;92(11):2845-55
references: 11753958
references: J Asian Nat Prod Res. 2011 Mar;13(3):242-50
references: 21409686
references: Afr J Tradit Complement Altern Med. 2013;10(6):435-8
references: 24311863
references: J Zhejiang Univ Sci B. 2006 Mar;7(3):245-50
references: 16502514
references: Anticancer Drugs. 2014 Feb;25(2):161-73
references: 24231526
references: Zhongguo Dang Dai Er Ke Za Zhi. 2012 Oct;14(10):780-4
references: 23092573
references: Cell Physiol Biochem. 2012;30(3):631-41
references: 22832383
references: Int J Radiat Oncol Biol Phys. 1998 Jul 1;41(4):755-62
references: 9652835
references: PLoS One. 2012;7(2):e31055
references: 22363545
references: Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008 Oct;28(10):907-11
references: 19123329
references: Pharm Biol. 2013 Jul;51(7):844-50
references: 23627473
references: Clin Chim Acta. 2005 Apr;354(1-2):91-9
references: 15748604
references: Mol Med Rep. 2014 Dec;10(6):3059-67
references: 25322804
references: Eur J Pharm Sci. 2011 Dec 18;44(5):573-9
references: 22019524
references: PLoS One. 2013;8(9):e72927
references: 24039823
references: J Pharm Pharmacol. 2010 Apr;62(4):514-20
references: 20604842
references: Lancet. 2005 Jun 11-17;365(9476):2041-54
references: 15950718
references: Zhonghua Gan Zang Bing Za Zhi. 2007 Dec;15(12):914-7
references: 18171526
references: Cancer. 1993 Jul 1;72(1):196-200
references: 8508406
references: Cytotechnology. 2009 Apr;59(3):219-29
references: 19760125
references: BMC Cancer. 2010;10:647
references: 21106094
references: Basic Clin Pharmacol Toxicol. 2007 Jul;101(1):1-8
references: 17577309
references: Evid Based Complement Alternat Med. 2012;2012:595292
references: 23258989
references: PLoS One. 2012;7(10):e46853
references: 23056487
references: Oncol Lett. 2013 Sep;6(3):699-704
references: 24137393
references: FEBS J. 2011 Jan;278(1):16-27
references: 21087457